Vision loss and paresthesias in a young man.
Retina and Uveitis Services, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston.
Tavé
T
van Zyl
Retina and Uveitis Services, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston.
Thanos D
TD
Papakostas
Retina and Uveitis Services, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston.
Lucia
L
Sobrin
D000208:Acute Disease; D001766:Blindness / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D005451:Fluorescein Angiography; D005938:Glucocorticoids; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008776:Methylprednisolone Hemisuccinate / Q000627:therapeutic use; D010292:Paresthesia / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D011241:Prednisone / Q000627:therapeutic use; D012164:Retinal Diseases / Q000175:diagnosis* / Q000188:drug therapy; D055213:Retinal Pigment Epithelium / Q000473:pathology*; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy; D020293:Vasculitis, Central Nervous System / Q000175:diagnosis* / Q000188:drug therapy; D014792:Visual Acuity / Q000187:drug effects; D055815:Young Adult
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D008776:Methylprednisolone Hemisuccinate; D003520:Cyclophosphamide; D011241:Prednisone